Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2022-04-05 Director's Dealing
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2022-04-05 English
PRIMARY DOCUMENT
Director's Dealing
2022-04-04 English
PRIMARY DOCUMENT
Director's Dealing
2022-03-29 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to an underwritten public offering of common stock, including details about the underwriting agreement, share pricing, and expected proceeds. It also references a press release announcing the pricing of the offering. There are no financial statements or detailed financial performance data included, only an announcement of a financing event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is 7660 characters, sufficient to provide substantive details about the financing event. Therefore, the correct classification is CAP with high confidence.
2022-03-25 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering by Apellis Pharmaceuticals, Inc. It details the terms of the offering, underwriting discounts, use of proceeds, risk factors, and other information typical of a securities offering document. It is not a financial report, earnings release, or management discussion, but rather a capital raising document. The presence of underwriting details, offering price, and shares offered confirms this is a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to clear identification of the document type and content.
2022-03-25 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering by Apellis Pharmaceuticals, Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company overview. The presence of terms like 'prospectus supplement', 'common stock offering', 'underwriting discounts', and references to SEC registration and Rule 424(b)(5) clearly indicate this is a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive information about the offering, not just an announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2022-03-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.